Saturday, April 29, 2017
  Search 
Home
Opportunities
Partners
Publications
About Us
 
 
Please enter your email here, we would like to keep you informed.
 
 
Connect With Us - Facebook RSS
<April 2017>
SuMoTuWeThFrSa
1
2345678
9101112131415
16171819202122
23242526272829
30
Sections
Liberty In The News
Liberty Events
Conference Proceedings
Culture
Agriculture
Democracy
Development is the Key
Economic Freedom
Education for Life
Enterpreneurship
Environment
Freedom of Expression
Freedom to Trade
Globalization for the Good
Health is Wealth
Intellectual Property Rights
International Relations
Liberty is Security
Limited Government
Principles of Politics
Privatisation
Population - the ultimate resource
Property Rights
Regulatory Affairs
Rule of Law
Tax Freedom
Facts & Figures
Opportunities
Competitions
 Health is Wealth
 
Safe Medicines
American Enterprise Institute For Piblic Policy Research, United States Tuesday, May 18, 2010

Roger Bate
Barun Mitra
India is the largest generics manufacturing location in India. Though most drugs are of high quality, counterfeit and substandard drugs are a problem. The Government fails at putting a rein on local counterfeiters, writes Roger bate, Julian Harris, Barun Mitra and Lorraine Mooney

Many high quality drugs are manufactured in India, and the sub-continent has become the largest generics manufacturing location in the world. But it also has a significant problem with counterfeit and substandard drugs.

The enforcement of private rights (notably trademarks) must be given more support, both domestically and in international fora such as at WHO and with respect to the EU.

Further, the Government of India should not sponsor and promote reports which contain much misleading information concerning drug quality in India. Worse, some state governments have been very lenient towards local counterfeiters. In some instances officials have been directly bribed, and nearly all courts throughout the country have considerable backlogs of cases--allowing traders of potentially lethal products left free to ply an odious trade.

Our surveys show that a small but significant proportion of drugs purchased at retailers and traders in Delhi and retailers in Chennai fail at least one quality test. A significant minority of actors (manufacturers, wholesalers, pharmacies) are intentionally supplying counterfeit and substandard medicines in order to line their own pockets.

Fortunately private companies are finding innovative ways of preserving the identity of their products from counterfeiters, through serialisation systems (utilising new technologies) and more secure supply chains.

But such measures can only go so far. These companies, and patients, need the protection of the law, operated under efficient, independent and fair courts--both civil and criminal. Their prosperity and health relies on it.

This article was published in the American Enterprise Institute For Piblic Policy Research on Tuesday, May 18, 2010. Please read the original article here.
Authors :
Roger Bate is a resident fellow of the American Enterprise Institute , a U.S. think-tank
Mr Barun Mitra is the director of Liberty Institute, an independent public policy think tank in New Delhi.
Tags- Find more articles on - counterfeit | Delhi | drugs | India | Julian Harris | Lorraine Mooney | Roger bate | substandard

Post your Comments on this Article

Name  
Email    
Comment  
Comments will be moderated
Julian Harris

More Related Articles
Health is Wealth
More Articles


 
An Initiative of
LIBERTY INSTITUTE, INDIA
All rights reserved.